Explore ›
Finding
Finding
null
OnabotulinumtoxinA and anticholinergic therapy produced equivalent reductions in daily urgency urinary incontinence episodes over 6 months (3.3 vs 3.4 episodes/day reduction from a baseline of 5.0/day, P=0.81), with no significant difference between the two treatments.
| Effect size | 3.3 vs 3.4 episodes per day reduction |
| Follow-up | 6 months |
| Comparator | Anticholinergic therapy (solifenacin 5-10 mg daily, with option to switch to trospium XR 60 mg) |
| Effect summary | null; 3.3 vs 3.4 episodes per day reduction |
| Effect modifiers | [{"modifier": "Prior anticholinergic use", "interaction_p": "p=0.16", "direction": "null", "stratum_details": "Treatment effect did not differ by prior anticholinergic exposure vs no prior exposure", "plain_language": "Whether or not you've tried anticholinergic pills before doesn't change how well either treatment works", "annotation_notes": ""}, {"modifier": "Baseline UUI severity", "interaction_p": "p=0.53", "direction": "null", "stratum_details": "Treatment effect did not differ by baseline frequency (5-8 vs >=9 episodes per 3-day period). Higher baseline frequency associated with greater absolute reduction (p<0.001) regardless of treatment group.", "plain_language": "Both treatments work equally well whether your incontinence is moderate or severe, though women with worse symptoms improved more in absolute terms", "annotation_notes": ""}] |
Connected entities
Conditions
Outcomes
Populations
Source
PMC3543828
Anticholinergic Therapy vs. OnabotulinumtoxinA for Urgency Urinary Incontinence